医学临床研究
  2025年7月8日 星期二           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2023, Vol. 40 Issue (12): 1936-1939    DOI: 10.3969/j.issn.1671-7171.2023.12.033
  论著 本期目录 | 过刊浏览 | 高级检索 |
左西孟旦联合托伐普坦治疗急性失代偿性HFpEF的效果
马睿1, 雷雪婷2*
1.陕西航天医院,陕西 西安 710025;
2.陕西省山阳县人民医院,陕西 商洛 726400
The Effect of Levosimendan Combined with Tofacilitaxel in the Treatment of Acute Decompensated HFpEF
MA Rui, LEI Xueting
Shaanxi Aerospace Hospital, Xi'an Shaanxi 710025
全文: PDF (1241 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨左西孟旦联合托伐普坦治疗急性失代偿性射血分数保留心力衰竭(HFpEF)患者的临床效果。【方法】选取2020年3月至2021年11月陕西航天医院收治的78例急性失代偿性HFpEF患者,采用随机数字表法将其分为观察组和对照组,每组39例。对照组给予托伐普坦片治疗,观察组在对照组基础上联合左西孟旦治疗。两组患者均于治疗前及治疗1周后评估心功能指标[左心室舒张/收缩末期内径(LVEDD/LVESD)及左心室射血分数(LVEF)]、心肌损伤相关指标[心型脂肪酸结合蛋白(hFABP)及N-末端脑钠肽前体(NT-proBNP)]、心功能相关炎症因子指标[超敏C反应蛋白(hs-CRP)及缺氧诱导因子1α(HIF-1α)]、血流动力学指标[心率(HR)、每搏输出量(SV)]及24 h尿量水平,并记录药物不良反应。【结果】治疗后,两组LVEDD、LVESD低于治疗前,LVEF高于治疗前,观察组LVEDD、LVESD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05);两组患者血清hFABP、NT-proBNP、hs-CRP、HIF-1α水平低于治疗前,观察组低于对照组(P<0.05);两组患者SV及24 h尿量高于治疗前,HR低于治疗前,观察组SV及24 h尿量高于对照组(P<0.05)。观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。【结论】左西孟旦联合托伐普坦应用于急性失代偿性HFpEF患者治疗中,有助于患者心功能恢复,稳定血流动力学且安全性良好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
马睿
雷雪婷
关键词 心力衰竭/药物疗法急性病左西孟旦/药理学托伐普坦/药理学    
Abstract:【Objective】To explore the clinical efficacy of levosimendan combined with tofacilitan in patients with acute decompensated ejection fraction preserved heart failure (HFpEF). 【Methods】A total of 78 patients with acute decompensated HFpEF admitted to Shaanxi Aerospace Hospital from March 2020 to November 2021 were selected and randomly divided into an observation group and a control group using a random number table method, with 39 cases in each group. The control group was treated with Tovastatin tablets, while the observation group was treated with a combination of levosimendan on the basis of the control group. Both groups of patients were evaluated for cardiac function indicators [left ventricular end diastolic/systolic diameter (LVEDD/LVESD) and left ventricular ejection fraction (LVEF)], myocardial injury related indicators [heart type fatty acid binding protein (hFABP) and N-terminal B-type brain natriuretic peptide(NT-proBNP)], and cardiac function related inflammatory factor indicators [high-sensitivity C-reactive protein (hs-CRP) and hypoxia inducible factor 1α (HIF-1α)] before and 1 week after treatment Hemodynamic indicators [heart rate (HR), stroke output (SV)] and 24-hour urine output levels, and adverse drug reactions were recorded.【Results】After treatment, LVEDD and LVESD in both groups were lower than before treatment, and LVEF was higher than before treatment. LVEDD and LVESD in the observation group were lower than those in the control group, and LVEF was higher than those in the control group, with statistical significance (P<0.05); The serum levels of hFABP, NT-proBNP, hs-CRP, and HIF-1α in two groups of patients were lower than before treatment, and the observation group was lower than the control group (P<0.05); The SV and 24-hour urine output of the two groups of patients were higher than before treatment, while the HR was lower than before treatment. The observation group had higher SV and 24-hour urine output than the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). 【Conclusion】The combined use of levosimendan and tofapetam in the treatment of acute decompensated HFpEF patients is beneficial for the recovery of cardiac function, stable hemodynamics, and good safety.
Key wordsHeart Failure/DT    Acute Disease    Simendan/PD    Tolvaptan/PD
收稿日期: 2022-10-06     
中图分类号:  R541.61  
通讯作者: *E-mail:LL20227133@163.com   
引用本文:   
马睿, 雷雪婷. 左西孟旦联合托伐普坦治疗急性失代偿性HFpEF的效果[J]. 医学临床研究, 2023, 40(12): 1936-1939.
MA Rui,LEI Xueting. The Effect of Levosimendan Combined with Tofacilitaxel in the Treatment of Acute Decompensated HFpEF. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1936-1939.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.12.033     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I12/1936
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn